INDEX OF SUBJECTS FOR VOLUME 42

Acinetobacter spp.
  A. baumannii, typing of nosocomial isolates, 328
  amikacin resistance, 283
  characterisation by Biolog system, 113
Actin condensation, by *P. alcalifaciens*, 186
Adherence
  campylobacters to epithelial cells, 316
  of enterotoxigenic *E. coli*, 3
  inhibition by milk proteins, 3
Aeromonas spp.
  A. hydrophila, bacteraemia, 171
  A. hydrophila, virulence factors, 171
  temperature-dependent expression of lipopolysaccharides, 32
  temperature-dependent expression of proteins, 32
  and travellers' diarrhoea, 26
Agglutination, fibronectin-coated latex beads by staphylococci, 96
AIDS patients, and *P. carinii* pneumonia, 394
Alcohols, effects on *P. aeruginosa* phage F116, 415
Amikacin resistance, and gram-negative bacilli, 283
Aminoglycoside resistance, and *M. fermentans*, 421
Antibiotic resistance
  amikacin, and gram-negative bacilli, 283
  aminoglycosides, and *M. fermentans*, 421
  methicillin, and *S. aureus*, 62, 214
  polymyxin B, and *V. cholerae*, 20
  quinolones, and MRSA, 214
Antibiotics and other antimicrobial substances
  azithromycin, post-antibiotic effect on streptococci, 362
  effects of biocides on phage F116, 415
  erythromycin, post-antibiotic effect on streptococci, 362
  monensin, effect on *L. pneumophila*, 269
  susceptibility of *A. baumannii*, 328
  susceptibility of *M. fermentans*, 421
  vancomycin, monitoring serum levels, 309
Antibodies
  against *B. melitensis*, 200
  against chlamydia, 191
  against influenza virus, 53
  against *P. carinii*, 120, 231
Antigens
  of *B. melitensis*, 200
  colonisation factor, of *E. coli*, 3
  cyst and trophozoite, of *P. carinii*, 120
  fimbrial, of *P. gingivalis*, 165
  of group B streptococci, 246
  of influenza virus, 53
  ISCOM preparations, 53
  superantigenic exotoxin of *S. aureus*, 91
  of *V. cholerae*, 251
Antisera
  against *P. carinii*, 120
  against *V. cholerae*, 251
Arthroconidia, of *T. mentagrophytes*, 225
Aspergillosis, 299
Aspergillus fumigatus, RAPD analysis of virulence, 299
Astroviruses, 1
Azithromycin, post-antibiotic effect on streptococci, 362

Bacilli
  bubonic plague, 383
  gram-negative, amikacin resistance, 283
Bacteraemia
  A. hydrophila, 171
  influence of immunosuppressive agents, 181
  S. aureus, 43
  S. epidermidis, 156
Bacteriophage *see* Phage
Bacteroides
  B. fragilis, biological activity of LPS, 102
  biological activity of LPS, 102
Basophils, effects of *H. pylori* on histamine release, 386
Biocides, effects on *P. aeruginosa* phage F116, 415
Biolog system, 113
Biotyping, *A. baumannii*, 328
Black Death, 383
Blastocystis hominis, biochemical characterisation, 304
Bone marrow transplantation, 156
BOOKS RECEIVED
  Achieving Sterility in Medical and Pharmaceutical Products (N. A. Halls), 230
  Bailey and Sott's Diagnostic Microbiology, 9th edition (E. J. Baron, L. R. Peterson and S. M. Finegold), 308
  Chemical Methods in Prokaryotic Systematics (Edited by M. Goodfellow and A. G. O'Donnell), 152
  Edinburgh's Contribution to Medical Microbiology (C. J. Smith and J. G. Collee), 74
  Medical Intelligence Unit—Strategies in Vaccine Design (G. L. Ada), 74
  Notes on Medical Bacteriology 4 (J. D. Sleigh and M. C. Timbury), 230
  Obstetric and Gynecologic Infectious Diseases (Edited by J. G. Pastorek), 152
  Pathogenic and Clinical Microbiology. A Laboratory Manual (S. S. Rowland, S. Ross Walsh, L. D. Teel and A. M. Carnahan), 308
  PCR Technology. Current Innovations (Edited by H. G. Griffin and A. M. Griffin), 74
  Pseudomonas aeruginosa. Infections and Treatment (Edited by A. L. Baltch and R. P. Smith), 454
  Viral Infections of the Heart (Edited by J. E. Banatvala), 152
  Viruses and Cancer (Edited by A. Minson, J. Neil and M. McCrae), 308
Bovine spongiform encephalopathy, 153
Brucella
  B. abortus, and macrophage repopulation, 133
  B. melitensis, immunogenic properties of cell-wall fractions, 200
  B. melitensis, monoclonal antibody, 200
Bubonic plague
  diagnosis, 383
  historical aspects, 383

Campylobacters
  biological characteristics, 312
  clinical aspects, 314
  epidemiology, 314
  flagella, 316
  genetic characteristics, 312, 319
  haemolytic activity, 175
  lipopolysaccharide, 318
  pathogenesis, 316
  plasmids, 313
  toxins, 318
  transmission, 315
  virulence factors, 316
Candida spp.
  C. albicans in oral candidosis, 372
  and complement production in monocytes, 291
  and cytokine production in monocytes, 291
Candidosis, oral, 372
Capsule, of group B streptococci, 246
Cell culture
  adherence of campylobacters to epithelial cells, 317
  detection of *P. carinii* in monocytes, 394
  effect of monensin on *L. pneumophila* in HeLa cells, 269
  invasion of HEp-2 cells by *P. alcalifaciens*, 186
  monocytic, replication of *C. pneumoniae*, 191
  monocytic, replication of *C. trachomatis*, 191
  responses of monocytes to yeasts, 291
Cetylpyridinium chloride, effects on *P. aeruginosa* phage F116, 415
Chemotactic response, leucocytes to *E. coli*, 196
Children
  clostridial infection in, 78
  immunisation with Hib vaccine, 75

Porphyromonas infections in, 340
Prevotella infections in, 340
Chlamydia
C. pneumoniae, replication in monocytes, 191
C. trachomatis, replication in monocytes, 191
Cholera, 20
Cholera toxin, 251
Chromatography, thiophilic adsorption, 10
Cisplatin, and endogenous bacteraemia, 181
Clostridia
C. difficile toxin A, inhibition of binding, 10
infections in children, 78
Colonisation factor antigen, 3
Complement
yeast-induced production of C3 and factor B, 291
Creutzfeldt-Jakob disease, 153
Cyclophosphamide, and endogeneous bacteraemia, 181
Cyst antigens of *P. carinii*, 120
Cysteine-requiring *E. coli*, 39
Cystic fibrosis patients, 220
Cytokine production
during *S. typhimurium* sepsis, 348
monocyte responses elicited by yeasts, 291
and *P. gingivalis*, 165
Cytotoxins
of campylobacters, 318
of *Helicobacter* spp., 48

Diarrhoea
astrovirus infection, 1
campylobacter infections, 314
travellers', *V. parahaemolyticus* infection, 83
travellers', and *Aeromonas* spp., 26
DNA
characterisation of *Acinetobacter* strains, 113
characterisation of *E. coli* O157:H7, 258
detection of hepatitis C virus by RT–PCR, 367
detection of *P. carinii* by PCR, 209
genes encoding synergohymenotropic toxins in *S. aureus*, 237
genotypic relationship of *C. albicans* in oral candidosis, 372
RAPD analysis of *A. fumigatus*, 299
rapid identification of leptospiras by RAPD, 336

Electronmicroscopy
effects of biocides on *P. aeruginosa* phage F116, 415
infection of nasal mucosal explants by *N. meningitidis*, 353
scanning, 353
transmission, 353
Electrophoresis
enzyme analysis, 442
pulsed-field gel, 127, 237, 258, 328
see also PAGE: SDS–PAGE
Encephalopathies, transmissible spongiform, 153
Endotoxins, of *Bacteroides* spp., 102
Enterobacteriaceae, amikacin resistance, 283
Enterococci,
monitoring serum levels of vancomycin in infection, 309
Enterocolitis, and campylobacters, 314
Enterotoxins, of *S. aureus*, 43
Enzyme electrophoresis, 442
Epidemiology
campylobacter infections, 314
E. coli O157:H7, 258
synergohymenotropic toxin-producing *S. aureus*, 237
typing nosocomial *A. baumannii* infections, 328
Erythromycin, post-antibiotic effect on streptococci, 362
Escherichia coli
back mutations to TEM-1 β-lactamase, 429
characterisation of O157:H7 isolates, 258
chemotactic responses of leucocytes, 196
colonisation factor antigen, 3
cysteine-requiring, 39
enteroinvasive (EIEC), 196
enterotoxigenic (ETEC), 3
epidemiology, 258
in haemolytic uraemic syndrome, 404
inhibition of adherence by milk proteins, 3
inhibition of haemagglutination, 3
plasmids, 258, 427
Shiga-like toxin genes, 404
in urinary tract infections, 39
virulence factors, 39, 196
Exotoxins, of *S. aureus*, 91

Faeces
characterisation of *P. alcalifaciens* isolates, 186
Fatal familial insomnia, 153
Fatty acids, unsaturated, effects on *H. pylori*, 276
Feline immunodeficiency virus infection
antiviral therapy, 233
epidemiology, 233
as a model for HIV and AIDS, 233
vaccines, 233
Fibronectin, staphylococcal fibronectin-binding gene, 96
Fimbriae, of *P. gingivalis*, 165
Flagella, of campylobacters, 316
Fluorouracil, and endogenous bacteraemia, 181
Furuncles, 237

Gastro-enteritis, astrovirus infection, 1
Gerstmann-Sträussler-Scheinker disease, 153
Glutaraldehyde, effects on *P. aeruginosa* phage F116, 415
Granulocyte-macrophage colony-stimulating factor, yeast-induced, 291

Haemagglutination
by *V. cholerae*, 251
inhibition, and *E. coli*, 3
Haemolysins
of campylobacters, 175
of *V. parahaemolyticus*, 83
Haemolytic uraemic syndrome, 404
Haemophilus influenzae, Hib vaccine, 75
Helicobacter spp.
H. hepaticus, cytotoxin production, 48
H. pylori, cytotoxin production, 48
H. pylori, effects on histamine release, 386
H. pylori, effects of unsaturated fatty acids, 276
hepatotoxin production, 48
Hepatitis, *Helicobacter* spp. in, 48
Hepatitis C virus, detection by RT–PCR method, 367
Hepatotoxin, production by *Helicobacter* spp., 48
Histamine release, and *H. pylori*, 386
HIV infection
detection of virus in monocytes, 411
FIV as a model for, 233
and *P. carinii* pneumonia, 231, 394
Hybridisation, characterisation of *Acinetobacter* strains, 113
Hydrophobicity, of streptococci, 362

Immune response
modulatory action of *H. pylori*, 386
to *B. abortus*, 133
to influenza virus vaccine, 53
to *P. gingivalis*, 165
Immunisation
impact of Hib vaccine, 75
mice against *B. melitensis*, 200
mice against influenza virus, 53
mice against *P. gingivalis*, 165
Immunoblotting, antigens of *P. carinii*, 120
Immunoglobulins
IgA, and *C. difficile* toxin A, 10
IgA in human milk, 10
IgE response and *H. pylori*, 386
IgG, against influenza virus vaccine, 53
Immunosuppressive agents, influence on endogenous bacteraemia, 181
Influenza virus
subunit antigens, 53
vaccines, 53
Interleukin stimulation, 348
Iso-enzyme analysis, of *B. hominis*, 304

Kawasaki syndrome, 91
Kuru, 153

β-Lactamase
  back mutations from TRC-1 to TEM-1, 429
  production by *Porphyromonas* spp., 340
  production by *Prevotella* spp., 340
Lactoferrin, and adhesion of *E. coli*, 3
Lasers, killing of MRSA by low-power light, 62
Legionella pneumophila
  effect of monensin on invasiveness and multiplication, 269
  mouse model of Legionnaires' disease, 433
Legionnaires' disease, 433
Leptospiras, identification by RAPD fingerprinting, 336
Leucocidin, Panton-Valentine, 237
Leucocytes
  chemotactic response to *E. coli*, 196
  phagocytosis and post-antibiotic effect, 362
Limulus amoebocyte assay, 102
Lipopolysaccharide (LPS)
  B. melitensis, immunogenic properties, 200
  bacteroides, biological activity, 102
  of campylobacters, 319
  of *S. typhimurium*, 348
  temperature-dependent expression in *Aeromonas* spp., 32
  of *V. cholerae*, 251
Lymphocytes, detection of HIV-1 in, 411
Lysogens, phage lysogens of *V. cholerae*, 399

Macrophages, repopulation, and *B. abortus*, 133
Mast cells, effect of *H. pylori* on histamine release, 386
Meningitis, *H. influenzae*, 75
Meningococci *see N. meningitidis*
Methicillin-resistant *S. aureus*, 62, 214
Methotrexate, and endogenous bacteraemia, 181
Milk
  free secretory component, and adhesion of *E. coli*, 3
  inhibition of binding of *C. difficile* toxin A, 10
  lactoferrin, and adhesion of *E. coli*, 3
Monensin, effect on *L. pneumophila*, 269
Monoclonal antibodies
  against *B. melitensis*, 200
  against *P. carinii*, 231
Monocytes
  chemotactic response to *E. coli*, 196
  cytokine and complement responses to yeasts, 291
  detection of HIV-1 in, 411
  detection of *P. carinii* in, 394
  replication of chlamydia in, 191
Mouse model
  cytokine stimulation in *S. typhimurium* sepsis, 348
  immunisation against *B. melitensis*, 200
  immunisation against influenza virus, 53
  immunosuppressive agents and endogenous bacteraemia, 181
  Legionnaires' disease, 433
Mycoplasma fermentans
  antibiotic susceptibility, 421
  resistance to aminoglycosides, 421

Nasal mucosal explants, 353
Neisseria meningitidis,
  infection of nasal mucosal explants, 353
Neutrophils
  chemotactic response to *E. coli*, 196
  phagocytosis of *T. mentagrophytes*, 225
Nosocomial infections
  amikacin resistance in gram-negative bacilli, 283
  typing *A. baumannii*, 328

Oral infections
  C. albicans in denture stomatitis, 372
  pioneer streptococci in neonates, 67
Organ culture, nasal mucosal explants, 353

PAGE
  identification and typing of pyogenic streptococci, 442
  see also SDS–PAGE
Panton-Valentine leucocidin, 237
Particle agglutination assay, 96
Peracetic acid, effects on *P. aeruginosa* phage F116, 415
Phage
  effects of biocides on *P. aeruginosa* phage F116, 415
  lysogenic, of *V. cholerae*, 399
  typing of *S. aureus*, 237
  typing of *V. cholerae*, 20
Phagocytosis
  post-antibiotic effect of azithromycin, 362
  post-antibiotic effect of erythromycin, 362
  streptococci by polymorphonuclear leucocytes, 362
  T. mentagrophytes by neutrophils, 225
Plague *see* Bubonic plague
Plasmids
  amikacin resistance in gram-negative bacilli, 283
  characterisation of *E. coli* O157:H7, 258
  and *E. coli* β-lactamases, 429
  genetic characteristics of campylobacters, 313
  insertion mutagenesis and *Y. pestis*, 264
  typing of *A. baumannii*, 328
  of *V. cholerae*, 251
Pneumocystis carinii
  antibodies, 120
  cyst and trophozoite antigens, 120
  detection by PCR, 209
  laboratory diagnosis of pneumonia, 231
  in peripheral blood mononuclear cells, 394
  pneumonia, and HIV infection, 394
Pneumonia, *P. carinii* infection, 231, 394
Pneumonic plague, 383
Polymerase chain reaction (PCR)
  classification of Shiga-like toxin genes, 404
  detection of hepatitis C virus by RT–PCR, 367
  detection of HIV-1 in monocytes, 411
  detection of *P. carinii*, 209
  detection of staphylococcal fibronectin-binding gene, 96
  typing of *A. baumannii*, 328
Polymorphonuclear leucocytes (PMNLs),
  phagocytosis and post-antibiotic effect, 362
Polymyxin B, resistance and *V. cholerae*, 20
Porphyromonas spp.
  β-lactamase production, 340
  infections in children, 340
  P. gingivalis, Th1 and Th2 epitopes of fimbriae, 165
Prevotella spp.
  β-lactamase production, 340
  infections in children, 340
PROCEEDINGS OF THE PATHOLOGICAL SOCIETY OF GREAT BRITAIN AND IRELAND, 141
Proteins
  antigens of group B streptococci, 246
  biochemical characterisation of *B. hominis*, 304
  cell-surface, of *V. cholerae*, 251
  fibronectin-binding staphylococcal, 96
  outer-membrane, of *V. cholerae*, 20
  role in pathogenesis of campylobacters, 317, 319
  temperature-dependent expression in *Aeromonas* spp., 32
  whole-cell analysis of *A. baumannii*, 328
Providencia alcalifaciens
  actin condensation, 186
  invasion of HEp-2 cells, 186
Pseudomonas
  P. aeruginosa, bacteraemia, 181
  P. aeruginosa, in cystic fibrosis, 220
  P. aeruginosa, effects of biocides on phage F116, 415
  P. aeruginosa, mixed morphotype testing, 220

4-Quinolone resistance, and MRSA, 214

Random amplified polymorphic DNA (RAPD)
  analysis of *A. fumigatus*, 299
  rapid identification of leptospiras, 336
Restriction endonuclease analysis, of *C. albicans*, 372

Restriction fragment length polymorphism analysis
of *V. cholerae*, 20
Reverse transcription-polymerase chain reaction (RT–PCR), 367
Ribotyping, of *Aeromonas* spp., 26

Salmonella typhimurium
cytokine stimulation during sepsis, 348
Scrapie, 153
SDS–PAGE
characterisation of *B. hominis*, 304
milk components, 10
Serology
detection of hepatitis C virus by RT–PCR, 367
diagnosis of *P. carinii* pneumonia, 231
Serotyping, group B streptococci, 161, 246
Serratia marcescens, amikacin resistance, 283
Serum, monitoring levels of vancomycin, 309
Shiga-like toxin, 404
Sputum
mixed morphotype testing of *P. aeruginosa* isolates, 220
Staphylococci
fibronectin-binding gene, 96
monitoring serum levels of vancomycin in infection, 309
S. aureus, bacteraemia, 43
S. aureus, enterotoxins, 43
S. aureus, epidemiology, 237
S. aureus, fibronectin-binding gene, 96
S. aureus, in Kawasaki syndrome, 91
S. aureus, killing by laser light, 62
S. aureus, methicillin-resistant, 62, 214
S. aureus, phage typing, 237
S. aureus, and 4-quinolone resistance, 214
S. aureus, superantigenic exotoxins, 91
S. aureus, synergohymenotropic toxins, 237
S. aureus, toxic shock syndrome toxin-1, 91
S. aureus, typing, in nasal carriers, 127
S. epidermidis, bacteraemia, 156
Stomatitis, denture, 372
Streptococci
antigens, 246
capsule, 246
cell-surface hydrophobicity, 362
group B, 161, 246
oral, pioneer in neonates, 67
post-antibiotic effect of azithromycin, 362
post-antibiotic effect of erythromycin, 362
pyogenic, identification and typing, 442
serotyping, 161, 246
susceptibility to antibiotics, 362
viridans, 67

Temperature
influence on protein and LPS expression, 32
Tissue culture *see* Cell culture: Organ culture
TNF induction assay, 102
Torulopsis spp.
and complement production in monocytes, 291
and cytokine production in monocytes, 291
Toxic shock syndrome toxin-1, 91
Toxins
campylobacter, 318
Shiga-like, of *E. coli*, 404
superantigenic exotoxin production by *S. aureus*, 91
synergohymenotropic, of *S. aureus*, 237
toxin A of *C. difficile*, 10
see also Cytotoxins: Enterotoxins
Translocation, by campylobacters, 317
Transmissible spongiform encephalopathies, 153
Trichophyton mentagrophytes
phagocytosis by neutrophils, 225
Trophozoite antigens, of *P. carinii*, 120, 231
Tumour necrosis factor, 348

Urinary tract infections, *E. coli*, 39

Vaccines
against feline immunodeficiency virus, 233
against influenza virus, 53
H. influenzae type b conjugate (Hib), 75
ISCOM preparations, 53
Vancomycin, monitoring serum levels, 309
Vibrio spp.
V. cholerae, antigens, 251
V. cholerae, characterisation of strain O139, 251
V. cholerae, cholera toxin production, 251
V. cholerae, genesis of strain O139, 20
V. cholerae, haemagglutinating activity, 251
V. cholerae, lysogenic phage, 399
V. cholerae, outer-membrane proteins, 20
V. cholerae, plasmids, 251
V. parahaemolyticus, haemolysins, 83
V. parahaemolyticus, Kanagawa-phenomenon negative, 83
Virulence factors
A. fumigatus, 299
A. hydrophila, 171
camplyobacters, 175, 312
E. coli, 39, 196
Y. pestis, 264

Yersinia pestis
and insertion mutagenesis, 264
virulent non-capsulate variants, 264

INDEX OF AUTHORS FOR VOLUME 42

ABRAHAMSEN T G, *see* HØGÅSEN *et al.*, 291
AHMED H A, *see* KHULUSI *et al.*, 276
AKASAKA T, *see* TANAKA *et al.*, 214
ALBERT M J, ANSARUZZAMAN M, BHUIYAN N A, NEOGI P K B, FARUQUE A S G. Characteristics of invasion of HEp-2 cells by *Providencia alcalifaciens*, 186
AMAKO K, *see* HU *et al.*, 127
AMBROISE-THOMAS P, *see* MONDON *et al.*, 299
AMYES S G B, *see* THOMSON AND AMYES, 429
ANISIMOV A P, *see* DROZDOV *et al.*, 264
ANSARUZZAMAN M, *see* ALBERT *et al.*, 186

BAMFORD KATHLEEN B, *see* LUTTON *et al.*, 386
BARCLAY G R, *see* DELAHOOKE *et al.*, 102
BEEKEN W, FABIAN J, FENWICK J. The chemotactic response of blood neutrophils and monocytes to strains of *Escherichia coli* with different virulence characteristics, 196
BEGGS T S, *see* MAILLARD J-Y *et al.*, 415
BELL YVONNE, *see* RICHARDSON AND BELL, 225
BENNETT M, HART C A. Feline immunodeficiency virus infection—a model for HIV and AIDS?, 233
BERNAL MARIA DEL CARMEN, *see* QUIRÓS *et al.*, 411
BERNARDS ALEXANDRA T, DIJKSHOORN L, VAN DER TOORN J, BOCHNER B R, VAN BOVEN C P A. Phenotypic characterisation of *Acinetobacter* strains of 13 DNA–DNA hybridisation groups by means of the Biolog system, 113
BERT F, PICARD B, LAMBERT-ZECHOVSKY N, GOULLET P. Identification and typing pyogenic streptococci by enzyme electrophoretic polymorphism, 442
BEVANGER L, *see* KWAM *et al.*, 246
BHASIN NAVNEET, *see* PAJNI *et al.*, 20
BHUIYAN N A, *see* ALBERT *et al.*, 186
BOCHNER B R, *see* BERNARDS *et al.*, 113
BOPP V, *see* LÄMMLER *et al.*, 161
BORROW R, *see* READ *et al.*, 161
BOWDEN G H, *see* PEARCE *et al.*, 67
BROOK I. Clostridial infection in children, 78
BROOK I. *Prevotella* and *Porphyromonas spp.* in infections in children, 340
BUITING ANTOINETTE M J, DE ROVER ZEGERINE, VAN ROOIJEN NICO. *Brucella abortus* causes an accelerated repopulation of the spleen and liver of mice by macrophages after their liposome-mediated depletion, 133

CABEZAS TERESA, *see* QUIRÓS *et al.*, 411
CAPRIOLI A, *see* RÜSSMANN *et al.*, 404
CASTELLANI PASTORIS M, *see* GOLDONI *et al.*, 269
CATCHPOLE C, HASTINGS J G M. Measuring pre- and post-dose vancomycin levels—time for a change?, 309
CATTANI L, *see* GOLDONI *et al.*, 269
CHATTERTON J M W, JOSS A W L, PENNINGTON T H, HO-YEN D O. Differences exist in the immunoblotting profiles of cyst and trophozoite antigens of *Pneumocystis carinii*, 120
CHATTERTON J M W, *see* HO-YEN *et al.*, 231
CHEE Y W, *see* VADIVELU *et al.*, 171
CHIBA S, *see* NUMAZAKI *et al.*, 191
CLOECKAERT A, JACQUES I, LIMET J N, DUBRAY G. Immunogenic properties of *Brucella melitensis* cell-wall fractions in BALB/c mice, 200
COLE M F, *see* PEARCE *et al.*, 67
CONTINI C, MASTRANTONI S, ROMANI R, CULTRERA R, DELIA S. Evidence of *Pneumocystis carinii* in cell line cultures infected with peripheral blood mononuclear cells isolated from AIDS patients with *P. carinii* pneumonia, 394
COOK N, MYINT S. Astroviruses, 1
COOKSON B D, *see* KWAM *et al.*, 246
COUPPIE P, *see* PREVOST *et al.*, 237
CRIBIER B, *see* PREVOST *et al.*, 237
CULTRERA R, *see* CONTINI *et al.*, 394

DAS BISWAJIT, *see* PAJNI *et al.*, 20
DAVIES G, *see* MATHABA *et al.*, 372
DAY M J, *see* MAILLARD J-Y *et al.*, 415
DE ROVER ZEGERINE, *see* BUITING *et al.*, 133
DELAHOOKE D M, BARCLAY G R, POXTON I R. A re-appraisal of the biological activity of bacteroides LPS, 102
DELIA S, *see* CONTINI *et al.*, 394
DEVI SHAMALA, *see* TAY *et al.*, 175
DIJKSHOORN L, *see* BERNARDS *et al.*, 113
DOOLEY J S G, *see* TSO AND DOOLEY, 32
DOYLE M P, *see* MENG *et al.*, 258
DROZDOV I G, ANISIMOV A P, SAMOILOVA S V, YEZHOV I N, YEREMIN S A, KARLYSHEV A V, KRASILNIKOVA V M, KRAVCHENKO V I. Virulent non-capsulate *Yersinia pestis* variants constructed by insertion mutagenesis, 264
DUBRAY G, *see* CLOECKAERT *et al.*, 200

EFSTRATIOU A, *see* KWAM *et al.*, 246
EL MASRY N A, *see* MANSOUR *et al.*, 304
ENNIS MADELEINE, *see* LUTTON *et al.*, 386
ERGAZAKI M, *see* KARACHRISTOS *et al.*, 367
ERIKSEN N H R, *see* RØDER *et al.*, 43
ESPERSEN F, *see* RØDER *et al.*, 43
EVANS MISHELL, *see* PEARCE *et al.*, 67
EVANS R, JOSS A W L, PENNINGTON T H, HO-YEN D O. The use of a nested polymerase chain reaction for detecting *Pneumocystis carinii* from lung and blood in rat and human infection, 209

FABIAN J, *see* BEEKEN *et al.*, 196
FARRAR G H, *see* WILLIAMS *et al.*, 433
FARUQUE A S G, *see* ALBERT *et al.*, 186
FENWICK J, *see* BEEKEN *et al.*, 196
FINCH R G, *see* READ *et al.*, 353
FITZGEORGE R B, *see* WILLIAMS *et al.*, 433
FITZSIMMONS S P, *see* PEARCE *et al.*, 67
FLEURETTE J, *see* LINA *et al.*, 156
FOREY F, *see* LINA *et al.*, 156
FOX A, *see* READ *et al.*, 353
FOX J G, *see* TAYLOR *et al.*, 48
FRANKE S, *see* RÜSSMANN *et al.*, 404
FURUYA N, *see* HIRAKATA *et al.*, 181

GARCÍA D C, WOLOJ G M, PIÑEIRO S, SORDELLI D O, KAUFMAN S. An 8-year study of resistance to amikacin in gram-negative bacilli isolates from patients with nosocomial infection at one hospital in Argentina, 283
GARCÍA F, *see* QUIRÓS *et al.*, 411
GAUSTAD P, *see* HØGÅSEN *et al.*, 291
GAYET S, *see* PREVOST *et al.*, 237
GEMMELL C G, *see* RAMADAN *et al.*, 362
GEORGE R C, *see* KWAM *et al.*, 246
GERRITSEN M A, SMITS M A, OLYHOEK T. Random amplified polymorphic DNA fingerprinting for rapid identification of leptospiras of serogroup Sejroe, 336
GHAZI H O, POTTER C W, SMITH T L, JENNINGS R. Comparative antibody responses and protection in mice immunised by oral or parenteral routes with influenza virus subunit antigens in aqueous form or incorporated into ISCOMs, 53
GHOSE A C, *see* NANDY *et al.*, 251
GHOSH A, *see* MITRA *et al.*, 399
GHOSH AMIT, *see* PAJNI *et al.*, 20
GHOSH R K, *see* MITRA *et al.*, 399
GHOSH R K, *see* PAJNI *et al.*, 20
GIUGLIANO L G, RIBEIRO S T G, VAINSTEIN M H, ULHOA C J. Free secretory component and lactoferrin of human milk inhibit the adhesion of enterotoxigenic *Escherichia coli*, 3
GOLDONI P, CASTELLANI PASTORIS M, CATTANI L, PELUSO C, SINIBALDI L, ORSI N. Effect of monensin on the invasiveness and multiplication of *Legionella pneumophila*, 269

GOULLET P, *see* BERT *et al.*, 442
GRAY T, *see* READ *et al.*, 353
GRILLOT R, *see* MONDON *et al.*, 299

HALL G, *see* WILLIAMS *et al.*, 433
HANN A C, *see* MAILLARD J-Y *et al.*, 415
HANNAN P C T. Antibiotic susceptibility of *Mycoplasma fermentans* strains from various sources and the development of resistance to aminoglycosides *in vitro*, 421
HÄNNINEN M L, SALMI S, MATTILA L, TAIPALINEN R, SIITONEN A. Association of *Aeromonas* spp. with travellers' diarrhoea in Finland, 26
HARADA K, *see* TODOME *et al.*, 91
HARMSEN D, *see* RÜSSMANN *et al.*, 404
HART C A, *see* BENNETT AND HART, 233
HART C A. Transmissible spongiform encephalopathies, 153
HASTINGS J G M, *see* CATCHPOLE AND HASTINGS, 309
HAYAKAWA I, *see* TANAKA *et al.*, 214
HIRAKATA Y, FURUYA N, MATSUMOTO T, TATEDA K, YAMAGUCHI K. Influence of various immunosuppressive agents on the occurrence of endogenous bacteraemia in mice, 181
HO-YEN D O, CHATTERTON J M W, JOSS A W L. Laboratory diagnosis of *Pneumocystis carinii* pneumonia, 231
HO-YEN D O, *see* CHATTERTON *et al.*, 120
HO-YEN D O, *see* EVANS *et al.*, 209
HØGÅSEN A K M, ABRAHAMSEN T G, GAUSTAD P. Various *Candida* and *Torulopsis* species differ in their ability to induce the production of C3, factor B and granulocyte-macrophage colony-stimulating factor (GM-CSF) in human monocyte cultures, 291
HONDA T, *see* NAGAYAMA *et al.*, 83
HU L, UMEDA A, KONDO S, AMAKO K. Typing of *Staphylococcus aureus* colonising human nasal carriers by pulsed-field gel electrophoresis, 127
HUDSON R A, *see* MAILLARD J-Y *et al.*, 415

IGARASHI H, *see* TODOME *et al.*, 91
ISHIDA H, *see* TANAKA *et al.*, 214

JACQUES I, *see* CLOECKAERT *et al.*, 200
JENNINGS R, *see* GHAZI *et al.*, 53
JIMENEZ DE ANTA M T, *see* MARCOS *et al.*, 328
JOHNSON JOLENE, *see* PEARCE *et al.*, 67
JONES D M, *see* READ *et al.*, 353
JONES N, *see* READ *et al.*, 353
JOSS A W L, *see* CHATTERTON *et al.*, 120
JOSS A W L, *see* EVANS *et al.*, 209
JOSS A W L, *see* HO-YEN *et al.*, 231
JOTWANI R, TANAKA Y, WATANABE K, TANAKA K, KATO N, UENO K. Cytokine stimulation during *Salmonella typhimurium* sepsis in Ity^s mice, 348

KAR S, *see* MITRA *et al.*, 399
KAR SUDESHNA, *see* PAJNI *et al.*, 20
KARACHRISTOS A, LINARDOPOULOS S, ERGAZAKI M, SPANDIDOS D A. Detection and analysis of hepatitis C virus by a combined RT-PCR method: variation in the 5′ non-coding region of the viral genome, 367
KARCH H, *see* RÜSSMANN *et al.*, 404
KARLYSHEV A V, *see* DROZDOV *et al.*, 264
KATO N, *see* JOTWANI *et al.*, 348
KAUFMAN S, *see* GARCÍA *et al.*, 283
KAUTNER INGRID M, *see* TAY *et al.*, 175
KETLEY J. Virulence of *Campylobacter* species: a molecular genetic approach, 312
KHULUSI S, AHMED H A, PATEL P, MENDALL M A, NORTHFIELD T C. The effects of unsaturated fatty acids on *Helicobacter pylori in vitro*, 276
KONDO S, *see* HU *et al.*, 127
KOTANI S, *see* TODOME *et al.*, 91
KOTHE E, *see* RÜSSMANN *et al.*, 404
KOTSIOU G, *see* WOLTER *et al.*, 220
KRASILNIKOVA V M, *see* DROZDOV *et al.*, 264
KRAVCHENKO V I, *see* DROZDOV *et al.*, 264
KVAM A I, EFSTRATIOU A, BEVANGER L, COOKSON B D, MARTICORENA I F, GEORGE R C, MAELAND J A. Distribution of serovariants of group B streptococci in isolates from England and Norway, 246

LAMBERT-ZECHOVSKY N, *see* BERT *et al.*, 442
LÄMMLER CH, SCHWARZ S, WIBAWAN I W T, OTT E, BOPP V, MARTINEZ-TAGLE A. Comparison of streptococci of serological group B isolated from healthy carriers and active disease in Chile, 161
LEBEAU B, *see* MONDON *et al.*, 299
LIMET J N, *see* CLOECKAERT *et al.*, 200
LINA B, FOREY F, TIGAUD J D, FLEURETTE J. Chronic bacteraemia due to *Staphylococcus epidermidis* after bone marrow transplantation, 156
LINARDOPOULOS S, *see* KARACHRISTOS *et al.*, 367
LUDLAM H A, *see* MINHAS *et al.*, 96
LUTTON DEBORAH A, BAMFORD KATHLEEN B, O'LOUGHLIN B, ENNIS MADELEINE. Modulatory action of *Helicobacter pylori* on histamine release from mast cells and basophils *in vitro*, 386

MCBRIDE B W, *see* WILLIAMS *et al.*, 433
MCCORMACK J G, *see* WOLTER *et al.*, 220
MCIVER C J, TAPSALL J W. Virulence and other phenotypic characteristics of urinary isolates of cysteine-requiring *Escherichia coli*, 39
MAELAND J A, *see* KVAM *et al.*, 246
MAILLARD J-Y, HANN A C, BEGGS T S, DAY M J, HUDSON R A, RUSSELL A D. Electronmicroscopic investigation of the effects of biocides on *Pseudomonas aeruginosa* PAO bacteriophage F116, 415
MANSOUR M S, MIKHAIL E M, EL MASRY N A, SABRY A G, MOHAREB E W. Biochemical characterisation of human isolates of *Blastocystis hominis*, 304
MARCOS M A, JIMENEZ DE ANTA M T, VILA J. Correlation of six methods for typing nosocomial isolates of *Acinetobacter baumanii*, 328
MAROTO MARIA DEL CARMEN, *see* QUIRÓS *et al.*, 411
MARTICORENA I F, *see* KVAM *et al.*, 246
MARTINEZ-TAGLE A, *see* LÄMMLER *et al.*, 161
MASTRANTONI S, *see* CONTINI *et al.*, 394
MATHABA L T, DAVIES G, WARMINGTON J R. The genotypic relationship of *Candida albicans* strains isolated from the oral cavity of patients with denture stomatitis, 372
MATSUMOTO T, *see* HIRAKATA *et al.*, 181
MATTILA L, *see* HÄNNINEN *et al.*, 26
MENDALL M A, *see* KHULUSI *et al.*, 276
MENG J, ZHAO S, ZHAO T, DOYLE M P. Molecular characterisation of *Escherichia coli* O157:H7 isolates by pulsed-field gel electrophoresis and plasmid DNA analysis, 258
MIKHAIL E M, *see* MANSOUR *et al.*, 304
MILLER K, *see* READ *et al.*, 353
MINHAS T, LUDLAM H A, WILKS, M, TABAQCHALI S. Detection by PCR and analysis of the distribution of a fibronectin-binding protein gene (*fbn*) among staphylococcal isolates, 96
MITAWANI T, *see* NAGAYAMA *et al.*, 83
MITRA S N, KAR S, GHOSH R K, PAJNI S, GHOSH A. Presence of lysogenic phage in the outbreak strains of *Vibrio cholerae* O139, 399
MIZUSE M, *see* TODOME *et al.*, 91
MOHAREB E W, *see* MANSOUR *et al.*, 304
MONDON P, THÉLU J, LEBEAU B, AMBROISE-THOMAS P, GRILLOT R. Virulence of *Aspergillus fumigatus* strains investigated by random amplified polymorphic DNA analysis, 299
MONTEIL H, *see* PREVOST *et al.*, 237
MUKHOPADHYAY S, *see* NANDY *et al.*, 251
MYINT S, *see* COOK AND MYINT, 1

NAGAYAMA K, YAMAMOTO K, MITAWANI T, HONDA T. Characterisation of a haemolysin related to Vp-TDH produced by a Kanagawa phenomenon-negative clinical isolate of *Vibrio parahaemolyticus*, 83
NAIR G BALAKRISH, *see* PAJNI *et al.*, 20
NANDY R K, SENGUPTA T K, MUKHOPADHYAY S, GHOSE A C. A comparative study of the properties of *Vibrio cholerae* O139, O1 and other non-O1 strains, 251

NEOGI P K B, *see* ALBERT *et al.*, 186
NIELSEN L P, *see* RØDER *et al.*, 43
NORTHFIELD T C, *see* KHULUSI *et al.*, 276
NUMAZAKI K, SUZUKI K, CHIBA S. Replication of *Chlamydia trachomatis* and *C. pneumoniae* in the human monocytic cell line U-937, 191

OGAWA T, UCHIDA H, YASUDA K. Mapping of murine Th1 and Th2 helper T-cell epitopes on fimbriae from *Porphyromonas gingivalis*, 165
OHKUNI H, *see* TODOME *et al.*, 91
OHTANI N, *see* TODOME *et al.*, 91
OKIBAYASHI F, *see* TODOME *et al.*, 91
O'LOUGHLIN B, *see* LUTTON *et al.*, 386
OLYHOEK T, *see* GERRITSEN *et al.*, 336
ORSI N, *see* GOLDONI *et al.*, 269
OTT E, *see* LÄMMLER *et al.*, 161

PAJNI S, *see* MITRA *et al.*, 399
PAJNI SANGEETA, SHARMA CHARU, BHASIN NAVNEET, GHOSH AMIT, RAMAMURTHY T, NAIR G BALAKRISH, RAMAJAYAM S, DAS BISWAJIT, KAR SUDESHNA, ROYCHOWDHURY SAUMYA, GHOSH R K. Studies on the pathogenesis of *Vibrio cholerae* O139: identification of probable progenitor strains, 20
PATEL P, *see* KHULUSI *et al.*, 276
PEARCE CHERYL, BOWDEN G H, EVANS MISHELL, FITZSIMMONS S P, JOHNSON JOLENE, SHERIDAN M J, WIENTZEN R, COLE M F. Identification of pioneer viridans streptococci in the oral cavity of human neonates, 67
PELUSO C, *see* GOLDONI *et al.*, 269
PENNINGTON T H, *see* CHATTERTON *et al.*, 120
PENNINGTON T H, *see* EVANS *et al.*, 209
PETIAU P, *see* PREVOST *et al.*, 237
PHIPPS M, *see* VADIVELU *et al.*, 171
PICARD B, *see* BERT *et al.*, 442
PIEDROLA G, *see* QUIRÓS *et al.*, 411
PIEMONT Y, *see* PREVOST *et al.*, 237
PIÑEIRO S, *see* GARCÍA *et al.*, 283
POTTER, *see* GHAZI *et al.*, 53
POXTON I R, *see* DELAHOOKE *et al.*, 102
PREVOST G, COUPPIE P, PREVOST P, GAYET S, PETIAU P, CRIBIER B, MONTEIL H, PIEMONT Y. Epidemiological data on *Staphylococcus aureus* strains producing synergohymenotropic toxins, 237
PREVOST P, *see* PREVOST *et al.*, 237
PUTHUCHEARY S D, *see* VADIVELU *et al.*, 171
PUTHUCHEARY SAVITHRI D, *see* TAY *et al.*, 175

QUIRÓS EUGENIA, GARCÍA F, MAROTO MARIA DEL CARMEN, BERNAL MARIA DEL CARMEN, CABEZAS TERESA, PIEDROLA G. Human immunodeficiency virus type-1 can be detected in monocytes by polymerase chain reaction, 411

RAMADAN M A, TAWFIK A F, SHIBL A M, GEMMELL C G. Post-antibiotic effect of azithromycin and erythromycin on streptococcal susceptibility to phagocytosis, 362
RAMAJAYAM S, *see* PAJNI *et al.*, 20
RAMAMURTHY T, *see* PAJNI *et al.*, 20
READ R C, FOX A, MILLER K, GRAY T, JONES N, BORROW R, JONES D M, FINCH R G. Experimental infection of human nasal mucosal explants with *Neisseria meningitidis*, 353
RIBEIRO S T G, *see* GIUGLIANO *et al.*, 3
RICHARDSON M D, BELL YVONNE. Non-opsonic phagocytosis of *Trichophyton mentagrophytes* arthroconidia by human neutrophils *in vitro*, 225
RØDER B L, ERIKSEN N H R, NIELSEN L P, SLOTSBJERG T, ROSDAHL VIBEKE T, ESPERSEN F. No difference in enterotoxin production among *Staphylococcus aureus* strains isolated from blood compared with strains isolated from healthy carriers, 43
ROLFE R D, SONG W. Immunoglobulin and non-immunoglobulin components of human milk inhibit *Clostridium difficile* toxin A-receptor binding, 10
ROMANI R, *see* CONTINI *et al.*, 394
ROSDAHL VIBEKE T, *see* RØDER *et al.*, 43
ROYCHOWDHURY SAUMYA, *see* PAJNI *et al.*, 20
RUSSELL A D, *see* MAILLARD J-Y *et al.*, 415
RÜSSMANN H, KOTHE E, SCHMIDT H, FRANKE S, HARMSEN D, CAPRIOLI A, KARCH H. Genotyping of Shiga-like toxin genes in non-O157 *Escherichia coli* strains associated with haemolytic uraemic syndrome, 404

SABRY A G, *see* MANSOUR *et al.*, 304
SAKURAI S, *see* TODOME *et al.*, 91
SALMI S, *see* HÄNNINEN *et al.*, 26
SAMOILOVA S V, *see* DROZDOV *et al.*, 264
SATO K, *see* TANAKA *et al.*, 214
SCHMIDT H, *see* RÜSSMANN *et al.*, 404
SCHWARZ S, *see* LÄMMLER *et al.*, 161
SENGUPTA T K, *see* NANDY *et al.*, 251
SHARMA CHARU, *see* PAJNI *et al.*, 20
SHERIDAN M J, *see* PEARCE *et al.*, 67
SHIBL A M, *see* RAMADAN *et al.*, 362
SIITONEN A, *see* HÄNNINEN *et al.*, 26
SINIBALDI L, *see* GOLDONI *et al.*, 269
SLACK M P E. Invasive *Haemophilus influenzae* disease: the impact of Hib immunisation, 75
SLOTSBJERG T, *see* RØDER *et al.*, 43
SMITH T L, *see* GHAZI *et al.*, 53
SMITS M A, *see* GERRITSEN *et al.*, 336
SONG C, *see* TODOME *et al.*, 91
SONG W, *see* ROLFE AND SONG, 10
SORDELLI D O, *see* GARCÍA *et al.*, 283
SPANDIDOS D A, *see* KARACHRISTOS *et al.*, 367
SUZUKI H, *see* TODOME *et al.*, 91
SUZUKI K, *see* NUMAZAKI *et al.*, 191

TABAQCHALI S, *see* MINHAS *et al.*, 96
TAIPALINEN R, *see* HÄNNINEN *et al.*, 26
TANAKA K, *see* JOTWANI *et al.*, 348
TANAKA M, ZHANG Y X, ISHIDA H, AKASAKA T, SATO K, HAYAKAWA I. Mechanisms of 4-quinolone resistance in quinolone-resistant and methicillin-resistant *Staphylococcus aureus* isolates from Japan and China, 214
TANAKA Y, *see* JOTWANI *et al.*, 348
TAPSALL J W, *see* MCIVER AND TAPSALL, 39
TATEDA K, *see* HIRAKATA *et al.*, 181
TAWFIK A F, *see* RAMADAN *et al.*, 362
TAY SUN TEE, DEVI SHAMALA, PUTHUCHEARY SAVITHRI D, KAUTNER INGRID M. Detection of haemolytic activity of campylobacters by agarose haemolysis and microplate assay, 175
TAYLOR N S, FOX J G, YAN L. In-vitro hepatotoxic factor in *Helicobacter hepaticus*, *H. pylori* and other *Helicobacter* species, 48
THÉLU J, *see* MONDON *et al.*, 299
THOMSON C J, AMYES S G B. Back mutations to the TEM-1 β-lactamase from TRC-1 lead to restored sensitivity to clavulanic acid, 429
TIGAUD J D, *see* LINA *et al.*, 156
TODOME Y, OHKUNI H, MIZUSE M, OKIBAYASHI F, OHTANI N, SUZUKI H, SONG C, IGARASHI H, HARADA K, SAKURAI S, KOTANI S. Superantigenic exotoxin production by isolates of *Staphylococcus aureus* from the Kawasaki syndrome patients and age-matched control children, 91
TSO M D, DOOLEY J S G. Temperature-dependent protein and lipopolysaccharide expression in clinical *Aeromonas* isolates, 32
TWIGG G. Bubonic plague: doubts and diagnoses, 383

UCHIDA H, *see* OGAWA *et al.*, 165
UENO K, *see* JOTWANI *et al.*, 348
ULHOA C J, *see* GIUGLIANO *et al.*, 3
UMEDA A, *see* HU *et al.*, 127

VADIVELU J, PUTHUCHEARY S D, PHIPPS M, CHEE Y W. Possible virulence factors involved in bacteraemia caused by *Aeromonas hydrophila*, 171
VAINSTEIN M H, *see* GIUGLIANO *et al.*, 3
VAN BOVEN C P A, *see* BERNARDS *et al.*, 113

VAN DER TOORN J, *see* BERNARDS *et al.*, 113
VAN ROOIJEN NICO, *see* BUITING *et al.*, 133
VILA J, *see* MARCOS *et al.*, 328

WARMINGTON J R, *see* MATHABA *et al.*, 372
WATANABE K, *see* JOTWANI *et al.*, 348
WIBAWAN I W T, *see* LÄMMLER *et al.*, 161
WIENTZEN R, *see* PEARCE *et al.*, 67
WILKS M, *see* MINHAS *et al.*, 96
WILLIAMS A, MCBRIDE B W, HALL G, FITZGEORGE R B, FARRAR G H. Experimental Legionnaires' disease in SCID-Beige mice reconstituted with human leucocytes, 433
WILSON M, YIANNI C. Killing of methicillin-resistant *Staphylococcus aureus* by low-power laser light, 62
WOLOJ G M, *see* GARCÍA *et al.*, 283
WOLTER J M, KOTSIOU G, MCCORMACK J G. Mixed morphotype testing of *Pseudomonas aeruginosa* cultures from cystic fibrosis patients, 220

YAMAGUCHI K, *see* HIRAKATA *et al.*, 181
YAMAMOTO K, *see* NAGAYAMA *et al.*, 83
YAN L, *see* TAYLOR *et al.*, 48
YASUDA K, *see* OGAWA *et al.*, 165
YEREMIN S A, *see* DROZDOV *et al.*, 264
YEZHOV I N, *see* DROZDOV *et al.*, 264
YIANNI C, *see* WILSON AND YIANNI, 62

ZHANG Y X, *see* TANAKA *et al.*, 214
ZHAO S, *see* MENG *et al.*, 258
ZHAO T, *see* MENG *et al.*, 258